Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Consorzio Oncotech conducts clinical trials in oncology, notably a Phase 3 trial of fulvestrant as maintenance therapy post-chemotherapy in HER2-, hormone receptor positive metastatic breast cancer; patients randomized to receive maintenance fulvestrant or no treatment, with the main goal to improve progression-free survival.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Consorzio Oncotech.